08:00 , Feb 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Protein phosphatase magnesium-dependent 1d (PPM1D; WIP1) In vitro and mouse studies identified an allosteric inhibitor of WIP1 that could help treat cancer. WIP1 is...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Antisoma cancer news

Antisoma said it will seek partners for its development programs after concluding an offer period soliciting a sale of the biotech. Antisoma said it concluded the offer period to take a longer-term approach to explore...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

Antisoma cancer news

Antisoma reduced headcount to about 10 as part of its previously announced restructuring to save cash. The cuts include CMO Gray Acton. The company plans to further reduce headcount next month. In January, Antisoma announced...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Antisoma cancer news

Antisoma will reduce headcount by about 40-50 to about 10 by March 31 as part of its previously announced restructuring to save cash. Antisoma announced plans to immediately restructure last month after discontinuing development of...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

Amonafide L-malate: Development discontinued

Antisoma discontinued development of amonafide after data from the open-label, international Phase III ACCEDE trial in over 420 patients showed that 600 mg/m 2 IV amonafide for 5 days plus cytarabine missed the primary endpoint...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

AS1411: Phase IIb discontinued

Antisoma discontinued an open-label, international Phase IIb trial of AS1411 after early data from about 45 patients showed that the compound was unlikely to show a clear benefit. The company said it will focus on...
01:13 , Feb 1, 2011 |  BC Extra  |  Clinical News

Antisoma plunges after misses in AML

Antisoma plc (LSE:ASM) fell 4.03p (64%) to 2.22p on Monday after announcing that it discontinued development of acute myelogenous leukemia (AML) candidate amonafide ( AS1413 ). The decision came after data from the open-label, international...
07:00 , May 7, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease Protein phosphatase magnesium-dependent 1d (PPM1D; WIP1) A study in human cell culture and in mice suggests that agonizing WIP1...
07:00 , Oct 13, 2008 |  BC Week In Review  |  Company News

Antisoma, Institute of Cancer Research deal

Antisoma received worldwide, exclusive rights to develop and commercialize the institute's inhibitors of protein phosphatase magnesium-dependent 1 delta (PPM1D, WIP1 ) to treat cancer. The company and the institute will share preclinical responsibilities and costs....
07:00 , May 28, 2002 |  BC Week In Review  |  Company News

Tularik other research news

Researchers published in Nature Genetics evidence that PPM1D plays a role in breast cancer. PPM1D was amplified >2.5-fold in 27 of 164 primary breast tumors, and was overexpressed in amplified tumors and cell lines. In...